Carcinoma in situIntravesical therapyMitomycin CNon–muscle-invasive bladder cancerRandomized clinical trialUrinary bladderBACKGROUND: Bacillus Calmette-Gu茅rin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS). OBJECTIVE: Our aim was to assess if sequential mitomycin C (MMC) ...